The clinician - not Omzo - decides whether you get a prescription
Path 2 BMI of 27 or higher , plus a history of stroke or heart attack, prediabetes, or peripheral artery disease
doi: 10.1111/j.1748-1716.2010.02150.x 102 NozuTMiyagishiSKumeiSNozuRTakakusakiKOkumuraT
doi: 10.1038/bjc.2014.113 34 ChenJTChenCHKuKLHsiaoMChiangCPHsuTLet al
Nassar M., Nassar O., Abosheaishaa H., and Misra A., Decreased Risk of Recurrent Acute Pancreatitis With Semaglutide and Tirzepatide in People With Type 2 Diabetes or Obesity With a History of Acute Pancreatitis: A Propensity Matched Global Federated TriNetX DatabaseBased Retrospective Cohort Study, Diabetes and Metabolic Syndrome: Clinical Research and Reviews 18, no
Regulate blood sugar levels